Modus Therapeutics Holding AB (publ) (MODTX.ST)
SEK 1.21
(4.33%)
SEK 1.21
(4.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 16.4 Million SEK | -9.4% |
| 2022 | 18 Million SEK | -12.97% |
| 2021 | 20.69 Million SEK | 243.69% |
| 2020 | 6.02 Million SEK | -86.18% |
| 2019 | 43.57 Million SEK | -11.23% |
| 2018 | 49.09 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.8 Million SEK | 50.74% |
| 2024 Q1 | 3.18 Million SEK | -15.55% |
| 2023 Q1 | 5.8 Million SEK | -36.32% |
| 2023 FY | 16.31 Million SEK | -9.4% |
| 2023 Q4 | 3.77 Million SEK | 53.6% |
| 2023 Q3 | 2.45 Million SEK | -43.71% |
| 2023 Q2 | 4.36 Million SEK | -24.85% |
| 2022 Q3 | 2.82 Million SEK | -5.48% |
| 2022 Q1 | 3.06 Million SEK | -75.06% |
| 2022 Q2 | 2.99 Million SEK | -2.38% |
| 2022 FY | 18 Million SEK | -12.97% |
| 2022 Q4 | 9.12 Million SEK | 222.49% |
| 2021 FY | 20.69 Million SEK | 243.69% |
| 2021 Q1 | 1.42 Million SEK | 40.0% |
| 2021 Q4 | 12.28 Million SEK | 176.63% |
| 2021 Q3 | 4.44 Million SEK | 75.37% |
| 2021 Q2 | 2.53 Million SEK | 77.38% |
| 2020 Q4 | 1.02 Million SEK | 46.76% |
| 2020 Q1 | 2.6 Million SEK | 0.0% |
| 2020 FY | 6.02 Million SEK | -86.18% |
| 2020 Q3 | 695 Thousand SEK | -59.14% |
| 2020 Q2 | 1.7 Million SEK | -34.75% |
| 2019 FY | 43.57 Million SEK | -11.23% |
| 2018 FY | 49.09 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.917% |
| Camurus AB (publ) | 1.05 Billion SEK | 98.452% |
| Mendus AB (publ) | 129.13 Million SEK | 87.3% |
| Lipum AB (publ) | 37.3 Million SEK | 56.038% |
| NextCell Pharma AB | -576.01 Thousand SEK | 2947.302% |
| Simris Alg AB (publ) | 38.64 Million SEK | 57.557% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 42.1% |
| Active Biotech AB (publ) | 44.8 Million SEK | 63.398% |
| Amniotics AB (publ) | 29.07 Million SEK | 43.585% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -11.929% |
| BioArctic AB (publ) | 89.62 Million SEK | 81.701% |
| Cantargia AB (publ) | 290.01 Million SEK | 94.345% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 25.092% |
| CombiGene AB (publ) | 44.14 Million SEK | 62.847% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 88.53% |
| Genovis AB (publ.) | 88.19 Million SEK | 81.404% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 85.747% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -125.66% |
| Intervacc AB (publ) | 79.78 Million SEK | 79.444% |
| Kancera AB (publ) | 63.07 Million SEK | 73.998% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -197.173% |
| LIDDS AB (publ) | 27.75 Million SEK | 40.902% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -126.096% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 87.933% |
| OncoZenge AB (publ) | 15.9 Million SEK | -3.119% |
| Saniona AB (publ) | 1.07 Million SEK | -1422.841% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 94.899% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 95.414% |
| Xintela AB (publ) | 57.31 Million SEK | 71.385% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 90.975% |
| Ziccum AB (publ) | 27.87 Million SEK | 41.169% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 94.659% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 61.529% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 7.25% |
| Corline Biomedical AB | 30.16 Million SEK | 45.634% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 71.738% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 80.28% |
| Aptahem AB (publ) | 10.01 Million SEK | -63.798% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 87.824% |
| Fluicell AB (publ) | 28.61 Million SEK | 42.688% |
| Biovica International AB (publ) | 133.72 Million SEK | 87.735% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 17.125% |
| AcouSort AB (publ) | 25.87 Million SEK | 36.617% |
| Abliva AB (publ) | 27.86 Million SEK | 41.143% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 91.524% |
| 2cureX AB (publ) | 36.51 Million SEK | 55.088% |
| I-Tech AB | 40.14 Million SEK | 59.149% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 98.092% |
| Cyxone AB (publ) | 28.21 Million SEK | 41.869% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 85.004% |
| Biosergen AB | 26.8 Million SEK | 38.823% |
| Nanologica AB (publ) | 69.88 Million SEK | 76.532% |
| SynAct Pharma AB | 224.49 Million SEK | 92.694% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 62.874% |
| BioInvent International AB (publ) | 441.4 Million SEK | 96.284% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 31.532% |
| Alzinova AB (publ) | 36.39 Million SEK | 54.937% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 94.34% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -108.763% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 85.213% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -11.571% |